Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7462625 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
US6872728 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jan, 2021
(3 years ago) | |
US7419983 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods related thereto |
Jul, 2024
(2 months from now) | |
US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(4 months from now) | |
US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(15 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7179815 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Mar, 2021
(3 years ago) | |
US11459305 | ABBVIE | Processes for the preparation of uracil derivatives |
Nov, 2028
(4 years from now) | |
US10881659 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
US11045470 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(16 years from now) |
Oriahnn (Copackaged) is owned by Abbvie.
Oriahnn (Copackaged) contains Elagolix Sodium,Estradiol,Norethindrone Acetate; Elagolix Sodium.
Oriahnn (Copackaged) has a total of 10 drug patents out of which 3 drug patents have expired.
Expired drug patents of Oriahnn (Copackaged) are:
Oriahnn (Copackaged) was authorised for market use on 29 May, 2020.
Oriahnn (Copackaged) is available in capsule;oral dosage forms.
Oriahnn (Copackaged) can be used as management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids), management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) using 300 mg elagolix while co-administering omeprazole.
Drug patent challenges can be filed against Oriahnn (Copackaged) from 23 July, 2022.
The generics of Oriahnn (Copackaged) are possible to be released after 27 August, 2040.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
New Product(NP) | May 29, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids); Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) using 300 mg elagolix while c...
Dosage: CAPSULE;ORAL